Last reviewed · How we verify
SPC 1001 Mid2 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SPC 1001 Mid2 (SPC 1001 Mid2) — Shin Poong Pharmaceutical Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SPC 1001 Mid2 TARGET | SPC 1001 Mid2 | Shin Poong Pharmaceutical Co. Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SPC 1001 Mid2 CI watch — RSS
- SPC 1001 Mid2 CI watch — Atom
- SPC 1001 Mid2 CI watch — JSON
- SPC 1001 Mid2 alone — RSS
Cite this brief
Drug Landscape (2026). SPC 1001 Mid2 — Competitive Intelligence Brief. https://druglandscape.com/ci/spc-1001-mid2. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing